Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Clinical Research

Abstract LB-216: CSLEX (sialyl LewisX) is an important and useful tumor marker in monitoring breast cancer patients

Tomoyuki Fujita, Naoya Nagura, Kayoko Koshikawa, Hajime Nishimura, Ken-ichi Ito and Minoru Fujimori
Tomoyuki Fujita
1Tokyo Medical University Ibaraki Medical Center, Ami Inashiki, Ibaraki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naoya Nagura
1Tokyo Medical University Ibaraki Medical Center, Ami Inashiki, Ibaraki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kayoko Koshikawa
1Tokyo Medical University Ibaraki Medical Center, Ami Inashiki, Ibaraki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hajime Nishimura
1Tokyo Medical University Ibaraki Medical Center, Ami Inashiki, Ibaraki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ken-ichi Ito
2Shinshu University School of Medicine, Matsumoto, Nagano, Japan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Minoru Fujimori
1Tokyo Medical University Ibaraki Medical Center, Ami Inashiki, Ibaraki, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM10-LB-216 Published April 2010
  • Article
  • Figures & Data
  • Info & Metrics
Loading
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC

Abstract

Background: CSLEX-1 is one of the monoclonal antibodies for which the structure of the antigen is known. This antigen is called CSLEX (Sialyl Le X). It has been reported that CSLEX may be more useful than CEA in combination with CA15-3 in monitoring breast cancer patients.

Methods: We measured and evaluated the serum levels of some tumor markers, including CSLEX, in a total of 482 breast cancer patients with or without metastasis who consecutively visited the outpatient clinic of the Division of Breast and Endocrine Surgery, Shinshu University Hospital, between April 2007 and September 2007.

Results: All serum levels of tumor markers in a single measurement correlated significantly with the status of metastasis (P < 0.01). All combinations of combined measurements, such as CEA and CA15-3, CEA and NCC-ST439, CEA and CSLEX, CA15-3 and NCC-ST439, and CA15-3 and CSLEX, also correlated significantly with the status of metastasis (P < 0.01). The sensitivity, specificity, positive-predictive value, negative-predictive value and accuracy were almost the same between CSLEX and NCC-ST439, which belongs to the type II carbohydrate antigens. The cut-off values of serum CSLEX and NCC-ST439 were 38.8 ± 52.7 U/ml and 22.1 ± 27.8 U/ml, respectively (P = 0.16). Conclusions: These data support there are no differences between CSLEX and NCC-ST439 as diagnostic parameters in single or combined measurements. The cut-off value of serum CSLEX tended to be higher compared with that of NCC-ST439.

View this table:
  • View inline
  • View popup

Patient characteristics

View this table:
  • View inline
  • View popup

Diagnostic parameters for the detection of breast cancer metastasis using tumor markers (%)

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr LB-216.

  • ©2010 American Association for Cancer Research
Back to top
Cancer Research: 70 (8 Supplement)
April 2010
Volume 70, Issue 8 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract LB-216: CSLEX (sialyl LewisX) is an important and useful tumor marker in monitoring breast cancer patients
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract LB-216: CSLEX (sialyl LewisX) is an important and useful tumor marker in monitoring breast cancer patients
Tomoyuki Fujita, Naoya Nagura, Kayoko Koshikawa, Hajime Nishimura, Ken-ichi Ito and Minoru Fujimori
Cancer Res April 15 2010 (70) (8 Supplement) LB-216; DOI: 10.1158/1538-7445.AM10-LB-216

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract LB-216: CSLEX (sialyl LewisX) is an important and useful tumor marker in monitoring breast cancer patients
Tomoyuki Fujita, Naoya Nagura, Kayoko Koshikawa, Hajime Nishimura, Ken-ichi Ito and Minoru Fujimori
Cancer Res April 15 2010 (70) (8 Supplement) LB-216; DOI: 10.1158/1538-7445.AM10-LB-216
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Clinical Research

  • Abstract SY20-03: Novel radiotracers for clinical molecular imaging in oncology
  • Abstract PL01-02: The Breast International Group (BIG): Building on an accelerated path to tailored adjuvant cancer therapy
  • Abstract SS02-04: How much can we afford to pay for new drugs, and how do we make those decisions?
Show more 3

Poster Presentations - Late-Breaking Abstracts

  • Abstract LB-301: PLK1 inhibitor targets mismatch repair-deficient temozolomide-resistant tumors
  • Abstract LB-299: Glucose metabolism modulator HJC0152 differentially regulates glycolytic enzymes to suppress breast carcinogenesis
  • Abstract LB-335: Induction of Ribosomal Checkpoint Induced Senescence (RCIS) for the treatment of liver cancer
Show more 3

Late-Breaking Poster Presentations - Prognostic/Metastasis Biomarkers

  • Abstract LB-72: Expression of the BCL2-like 12 (BCL2L12) gene is associated with prolonged survival of breast adenocarcinoma patients.
  • Abstract LB-73: Circulating tumor cells with the invasive phenotype predict progression free survival and overall survival in preoperative patients diagnosed with advanced epithelial ovarian cancer.
  • Abstract LB-215: Hypoxia inducible factor-1 alpha (HIF-1α) splice variants: Potential prognostic biomarkers in breast cancer
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement